Detalles de la búsqueda
1.
Dose selection for a phase III study evaluating gepotidacin (GSK2140944) in the treatment of uncomplicated urogenital gonorrhoea.
Sex Transm Infect
; 99(1): 64-69, 2023 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-36411033
2.
Dose Selection for Phase III Clinical Evaluation of Gepotidacin (GSK2140944) in the Treatment of Uncomplicated Urinary Tract Infections.
Antimicrob Agents Chemother
; 66(3): e0149221, 2022 03 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34978887
3.
Pharmacokinetics of Oral Formulations of Gepotidacin (GSK2140944), a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor, in Healthy Adult and Adolescent Participants.
Antimicrob Agents Chemother
; 66(1): e0126321, 2022 01 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34633853
4.
Novel Bacterial Topoisomerase Inhibitor Gepotidacin Demonstrates Absence of Fluoroquinolone-Like Arthropathy in Juvenile Rats.
Antimicrob Agents Chemother
; 66(11): e0048322, 2022 11 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-36255258
5.
Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague.
Br J Clin Pharmacol
; 88(2): 416-428, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34289143
6.
Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK140944).
BMC Microbiol
; 21(1): 181, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-34130619
7.
A Phase IIa Study Evaluating Safety, Pharmacokinetics, and Antiviral Activity of GSK2838232, a Novel, Second-generation Maturation Inhibitor, in Participants With Human Immunodeficiency Virus Type 1 Infection.
Clin Infect Dis
; 71(5): 1255-1262, 2020 08 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-31769793
8.
Phase 2a Pharmacokinetic, Safety, and Exploratory Efficacy Evaluation of Oral Gepotidacin (GSK2140944) in Female Participants with Uncomplicated Urinary Tract Infection (Acute Uncomplicated Cystitis).
Antimicrob Agents Chemother
; 64(7)2020 06 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-32284384
9.
A Novel Inhaled Dry-Powder Formulation of Ribavirin Allows for Efficient Lung Delivery in Healthy Participants and Those with Chronic Obstructive Pulmonary Disease in a Phase 1 Study.
Antimicrob Agents Chemother
; 64(5)2020 04 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-32071044
10.
In Vitro Activity and Microbiological Efficacy of Gepotidacin from a Phase 2, Randomized, Multicenter, Dose-Ranging Study in Patients with Acute Bacterial Skin and Skin Structure Infections.
Antimicrob Agents Chemother
; 64(3)2020 02 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-31818823
11.
Using rapid point-of-care tests to inform antibiotic choice to mitigate drug resistance in gonorrhoea.
Euro Surveill
; 25(43)2020 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-33124551
12.
Gepotidacin for the Treatment of Uncomplicated Urogenital Gonorrhea: A Phase 2, Randomized, Dose-Ranging, Single-Oral Dose Evaluation.
Clin Infect Dis
; 67(4): 504-512, 2018 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-29617982
13.
Microbiological Analysis from a Phase 2 Randomized Study in Adults Evaluating Single Oral Doses of Gepotidacin in the Treatment of Uncomplicated Urogenital Gonorrhea Caused by Neisseria gonorrhoeae.
Antimicrob Agents Chemother
; 62(12)2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30249694
14.
A Phase I, Randomized, Double-Blinded, Placebo- and Moxifloxacin-Controlled, Four-Period Crossover Study To Evaluate the Effect of Gepotidacin on Cardiac Conduction as Assessed by 12-Lead Electrocardiogram in Healthy Volunteers.
Antimicrob Agents Chemother
; 61(5)2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28223381
15.
Efficacy, Safety, and Tolerability of Gepotidacin (GSK2140944) in the Treatment of Patients with Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections.
Antimicrob Agents Chemother
; 61(6)2017 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-28373199
16.
Correction to: Microbiome recovery in adult females with uncomplicated urinary tract infections in a randomised phase 2A trial of the novel antibiotic gepotidacin (GSK2140944).
BMC Microbiol
; 21(1): 293, 2021 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-34702186
17.
Penetration of GSK1322322 into epithelial lining fluid and alveolar macrophages as determined by bronchoalveolar lavage.
Antimicrob Agents Chemother
; 58(1): 419-23, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24189245
18.
Safety, tolerability, and efficacy of GSK1322322 in the treatment of acute bacterial skin and skin structure infections.
Antimicrob Agents Chemother
; 58(11): 6518-27, 2014 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-25136015
19.
Investigation of metabolism and disposition of GSK1322322, a peptidase deformylase inhibitor, in healthy humans using the entero-test for biliary sampling.
Drug Metab Dispos
; 42(8): 1314-25, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24872378
20.
Single-dose safety, tolerability, and pharmacokinetics of the antibiotic GSK1322322, a novel peptide deformylase inhibitor.
Antimicrob Agents Chemother
; 57(5): 2005-9, 2013 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-23403431